Janssen licensing agreement for Sepracor's norastemizole readies Hismanal alternative.
Executive Summary
JANSSEN READIES HISMANAL REPLACEMENT AS NEW WARNINGS are added to the labeling of the astemizole antihistamine product. Janssen announced Feb. 4 that it is licensing rights to Sepracor's astemizole metabolite norastemizole, giving the company an alternative product that could facilitate the removal of Hismanal from the market.